"Undruggable" No More: Takeaways from MassBio's 2026 Women's Health Symposium on Pancreatic Cancer - Massachusetts Biotechnology Council
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
“Undruggable.” For decades, that’s what researchers called RAS, the mutation behind about 90 percent of pancreatic cancers. Dr. Brian Wolpin of Dana-Farber Cancer Institute has a different answer: not yet.
He shared it yesterday at the MassBioHub, where we hosted our fourth annual Women’s Health Symposium with the Massachusetts Caucus of Women Legislators. This year’s focus was pancreatic cancer, which is personal for this community. The Caucus lost two members to the disease last year, Rep. Ann-Margaret Ferrante and Rep. Carol Doherty.
This article is an excerpt. To read the full content, visit the original source. Massachusetts Biotechnology Council
Related articles
Vitamin D drug may help crack pancreatic cancer’s protective shield - ScienceDaily
A small clinical trial led by researchers at Dana Farber Cancer Institute has tested a treatment strategy that began with laboratory discoveries at the Salk Institute. The idea is to activate the vitamin D receptor and, in doing so, alter the protective environment surrounding pancreatic tumors. That change could potentially make this notoriously difficult cancer more vulnerable to existing treatments. The study, published in Nature Cancer, included patients with previously untreated metastatic pancreatic cancer. Participants received standard chemotherapy either alone or in combination with paricalcitol, a vitamin D analog already approved by the FDA for other medical uses.
Bioengineer.org | Viral blips during HIV therapy are common and rarely signal treatment failure, Swedish study finds - European AIDS Treatment Group
Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.
European Medical Journal | HIV linked to early signs of heart dysfunction - European AIDS Treatment Group
European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.
0 comments
No comments yet. Be the first to share your thoughts!